Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
Orlistat is an oral inhibitor of gastrointestinal lipase used for weight reduction in obese patients. Although most adverse drug effects manifest in the gastrointestinal tract, this is the first reported case of orlistat-induced acute kidney injury secondary to acute oxalate nephropathy in a white woman with underlying chronic kidney disease. Acute kidney injury was associated temporally with an increased dose of orlistat and the development of increased fat malabsorption (more frequent loose oily stools). Urine sediment showed abundant calcium oxalate crystals and increased 24-hour urine oxalate concentration. Kidney biopsy showed deposition of calcium oxalate crystals within tubular lumens, consistent with acute oxalate nephropathy. Orlistat therapy was discontinued, and oral fluid intake was increased. A second kidney biopsy performed 1 month later to evaluate the slow resolution of kidney failure did not show calcium oxalate crystals within tubules. A steady improvement in renal function subsequently was observed. Results of a repeated 24-hour urine oxalate collection performed 3 weeks later when kidney function had improved were within normal limits.
Singh
Ashutosh
A
Department of Pathology, University of Tennessee Health Sciences Center, Memphis, TN, USA.
Sarkar
Shubho R
SR
Gaber
Lillian W
LW
Perazella
Mark A
MA
D000208:Acute Disease; D002129:Calcium Oxalate / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000378:metabolism*; D007783:Lactones / Q000009:adverse effects*; D008049:Lipase / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D000077403:Orlistat
D004791:Enzyme Inhibitors; D007783:Lactones; D002129:Calcium Oxalate; D000077403:Orlistat; D008049:Lipase